UA64714C2 - Dervatives of substituted 2-methyl benzimidazole, a method for preparing thereof, a pharmaceutical composition and a method for treatment of gastrointestinal diseases - Google Patents

Dervatives of substituted 2-methyl benzimidazole, a method for preparing thereof, a pharmaceutical composition and a method for treatment of gastrointestinal diseases Download PDF

Info

Publication number: UA64714C2
Authority: UA; Ukraine
Prior art keywords: compound according; compound; formula; pharmaceutically acceptable; acceptable salt
Prior art date: 1996-06-10

Application number

UA98126867A

Other languages

English (en)

Ukrainian (uk)

Original Assignee

Astra Ab

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1996-06-10

Filing date

1997-05-06

Publication date

2004-03-15

1997-05-06 Application filed by Astra Ab filed Critical Astra Ab

2004-03-15 Publication of UA64714C2 publication Critical patent/UA64714C2/uk

Links

238000000034 method Methods 0.000 title claims description 11
239000008194 pharmaceutical composition Substances 0.000 title claims description 10
208000018522 Gastrointestinal disease Diseases 0.000 title claims description 8
LDZYRENCLPUXAX-UHFFFAOYSA-N 2-methyl-1h-benzimidazole Chemical class C1=CC=C2NC(C)=NC2=C1 LDZYRENCLPUXAX-UHFFFAOYSA-N 0.000 title 1
125000000217 alkyl group Chemical group 0.000 claims abstract description 16
230000002265 prevention Effects 0.000 claims abstract description 7
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims abstract description 6
230000027119 gastric acid secretion Effects 0.000 claims abstract description 5
150000001875 compounds Chemical class 0.000 claims description 112
150000003839 salts Chemical class 0.000 claims description 23
238000004519 manufacturing process Methods 0.000 claims description 17
239000002253 acid Substances 0.000 claims description 15
230000015572 biosynthetic process Effects 0.000 claims description 13
125000000623 heterocyclic group Chemical group 0.000 claims description 11
239000004480 active ingredient Substances 0.000 claims description 9
229910052740 iodine Inorganic materials 0.000 claims description 9
238000006243 chemical reaction Methods 0.000 claims description 8
239000003814 drug Substances 0.000 claims description 8
230000002757 inflammatory effect Effects 0.000 claims description 7
230000005764 inhibitory process Effects 0.000 claims description 7
210000002784 stomach Anatomy 0.000 claims description 7
229910052736 halogen Inorganic materials 0.000 claims description 6
150000002367 halogens Chemical class 0.000 claims description 6
239000012442 inert solvent Substances 0.000 claims description 6
230000002401 inhibitory effect Effects 0.000 claims description 6
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical group Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 5
210000001156 gastric mucosa Anatomy 0.000 claims description 5
230000028327 secretion Effects 0.000 claims description 5
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 4
241000124008 Mammalia Species 0.000 claims description 4
208000015181 infectious disease Diseases 0.000 claims description 4
AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims description 3
239000004599 antimicrobial Substances 0.000 claims description 3
229910052757 nitrogen Inorganic materials 0.000 claims description 3
238000002560 therapeutic procedure Methods 0.000 claims description 3
239000002841 Lewis acid Substances 0.000 claims description 2
230000029936 alkylation Effects 0.000 claims description 2
238000005804 alkylation reaction Methods 0.000 claims description 2
150000002466 imines Chemical class 0.000 claims description 2
150000007517 lewis acids Chemical class 0.000 claims description 2
101001053401 Arabidopsis thaliana Acid beta-fructofuranosidase 3, vacuolar Proteins 0.000 claims 1
230000000845 anti-microbial effect Effects 0.000 claims 1
239000003937 drug carrier Substances 0.000 claims 1
229940058303 antinematodal benzimidazole derivative Drugs 0.000 abstract description 3
208000017189 Gastrointestinal inflammatory disease Diseases 0.000 abstract 1
125000003785 benzimidazolyl group Chemical class N1=C(NC2=C1C=CC=C2)* 0.000 abstract 1
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 47
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 33
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 33
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 27
238000012360 testing method Methods 0.000 description 20
239000002904 solvent Substances 0.000 description 14
-1 formic Chemical class 0.000 description 12
239000000203 mixture Substances 0.000 description 11
238000003786 synthesis reaction Methods 0.000 description 11
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 10
239000000741 silica gel Substances 0.000 description 10
229910002027 silica gel Inorganic materials 0.000 description 10
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 8
241000700159 Rattus Species 0.000 description 8
CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 8
238000002360 preparation method Methods 0.000 description 8
239000011734 sodium Substances 0.000 description 8
229910052708 sodium Inorganic materials 0.000 description 8
239000000243 solution Substances 0.000 description 8
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
230000009858 acid secretion Effects 0.000 description 7
239000002585 base Substances 0.000 description 7
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 6
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
238000004587 chromatography analysis Methods 0.000 description 6
230000002496 gastric effect Effects 0.000 description 6
BSMKWPQXLZDVIV-UHFFFAOYSA-N n-[(2,6-dimethylphenyl)methyl]-2-methyl-1h-benzimidazol-4-amine Chemical compound C=12NC(C)=NC2=CC=CC=1NCC1=C(C)C=CC=C1C BSMKWPQXLZDVIV-UHFFFAOYSA-N 0.000 description 6
229910052700 potassium Inorganic materials 0.000 description 6
239000011591 potassium Substances 0.000 description 6
FVAUCKIRQBBSSJ-UHFFFAOYSA-M sodium iodide Chemical compound [Na+].[I-] FVAUCKIRQBBSSJ-UHFFFAOYSA-M 0.000 description 6
XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 5
PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 5
229940079593 drug Drugs 0.000 description 5
239000004615 ingredient Substances 0.000 description 5
239000007788 liquid Substances 0.000 description 5
239000007787 solid Substances 0.000 description 5
230000000638 stimulation Effects 0.000 description 5
USVXDODAPOBXCF-UHFFFAOYSA-N 2-methyl-1h-benzimidazol-4-amine Chemical compound C1=CC=C2NC(C)=NC2=C1N USVXDODAPOBXCF-UHFFFAOYSA-N 0.000 description 4
HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 4
241000282472 Canis lupus familiaris Species 0.000 description 4
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
108010010803 Gelatin Proteins 0.000 description 4
239000013543 active substance Substances 0.000 description 4
229910052783 alkali metal Inorganic materials 0.000 description 4
150000001340 alkali metals Chemical class 0.000 description 4
239000008280 blood Substances 0.000 description 4
210000004369 blood Anatomy 0.000 description 4
238000001914 filtration Methods 0.000 description 4
239000008273 gelatin Substances 0.000 description 4
229920000159 gelatin Polymers 0.000 description 4
239000007903 gelatin capsule Substances 0.000 description 4
235000019322 gelatine Nutrition 0.000 description 4
235000011852 gelatine desserts Nutrition 0.000 description 4
239000012044 organic layer Substances 0.000 description 4
BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 4
229910000029 sodium carbonate Inorganic materials 0.000 description 4
229910052938 sodium sulfate Inorganic materials 0.000 description 4
235000011152 sodium sulphate Nutrition 0.000 description 4
239000000126 substance Substances 0.000 description 4
JIAARYAFYJHUJI-UHFFFAOYSA-L zinc dichloride Chemical compound [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 description 4
ITYRQASJHPCHMT-UHFFFAOYSA-N 4-[(2,6-dimethylphenyl)methoxy]-2-methyl-1h-benzimidazole Chemical compound C=12NC(C)=NC2=CC=CC=1OCC1=C(C)C=CC=C1C ITYRQASJHPCHMT-UHFFFAOYSA-N 0.000 description 3
ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
239000002775 capsule Substances 0.000 description 3
238000001704 evaporation Methods 0.000 description 3
230000008020 evaporation Effects 0.000 description 3
210000004051 gastric juice Anatomy 0.000 description 3
238000001802 infusion Methods 0.000 description 3
238000001990 intravenous administration Methods 0.000 description 3
INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 3
239000000843 powder Substances 0.000 description 3
239000000725 suspension Substances 0.000 description 3
HPVRFWQMBYLJRL-UHFFFAOYSA-N 2-(chloromethyl)-1,3-dimethylbenzene Chemical compound CC1=CC=CC(C)=C1CCl HPVRFWQMBYLJRL-UHFFFAOYSA-N 0.000 description 2
UIEARKBMUATCNI-UHFFFAOYSA-N 2-(chloromethyl)-1-ethyl-3-methylbenzene Chemical compound CCC1=CC=CC(C)=C1CCl UIEARKBMUATCNI-UHFFFAOYSA-N 0.000 description 2
HLPAESMITTURFN-UHFFFAOYSA-N 2-methyl-1h-benzimidazol-4-ol Chemical compound C1=CC=C2NC(C)=NC2=C1O HLPAESMITTURFN-UHFFFAOYSA-N 0.000 description 2
MPODUBZIKYZWNL-UHFFFAOYSA-N 4-[(4-fluoro-2,6-dimethylphenyl)methoxy]-1,2-dimethylbenzimidazole Chemical compound C1=CC=C2N(C)C(C)=NC2=C1OCC1=C(C)C=C(F)C=C1C MPODUBZIKYZWNL-UHFFFAOYSA-N 0.000 description 2
RPBZWVLCTKAFPX-UHFFFAOYSA-N 4-[(4-fluoro-2,6-dimethylphenyl)methoxy]-2-methyl-1h-benzimidazole Chemical compound C=12NC(C)=NC2=CC=CC=1OCC1=C(C)C=C(F)C=C1C RPBZWVLCTKAFPX-UHFFFAOYSA-N 0.000 description 2
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
229920000945 Amylopectin Polymers 0.000 description 2
206010002091 Anaesthesia Diseases 0.000 description 2
BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 2
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 2
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
229930195725 Mannitol Natural products 0.000 description 2
241001465754 Metazoa Species 0.000 description 2
241000283973 Oryctolagus cuniculus Species 0.000 description 2
239000002202 Polyethylene glycol Substances 0.000 description 2
102100037681 Protein FEV Human genes 0.000 description 2
101710198166 Protein FEV Proteins 0.000 description 2
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
229930006000 Sucrose Natural products 0.000 description 2
239000004098 Tetracycline Substances 0.000 description 2
150000007513 acids Chemical class 0.000 description 2
230000009471 action Effects 0.000 description 2
150000001412 amines Chemical class 0.000 description 2
229960003022 amoxicillin Drugs 0.000 description 2
LSQZJLSUYDQPKJ-NJBDSQKTSA-N amoxicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=C(O)C=C1 LSQZJLSUYDQPKJ-NJBDSQKTSA-N 0.000 description 2
230000037005 anaesthesia Effects 0.000 description 2
150000001556 benzimidazoles Chemical class 0.000 description 2
125000004432 carbon atom Chemical group C* 0.000 description 2
210000001715 carotid artery Anatomy 0.000 description 2
239000001913 cellulose Substances 0.000 description 2
229920002678 cellulose Polymers 0.000 description 2
MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 description 2
239000013078 crystal Substances 0.000 description 2
201000010099 disease Diseases 0.000 description 2
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
208000000718 duodenal ulcer Diseases 0.000 description 2
HHFAWKCIHAUFRX-UHFFFAOYSA-N ethoxide Chemical compound CC[O-] HHFAWKCIHAUFRX-UHFFFAOYSA-N 0.000 description 2
210000004211 gastric acid Anatomy 0.000 description 2
239000003112 inhibitor Substances 0.000 description 2
239000008101 lactose Substances 0.000 description 2
239000000594 mannitol Substances 0.000 description 2
235000010355 mannitol Nutrition 0.000 description 2
125000005905 mesyloxy group Chemical group 0.000 description 2
NBTOZLQBSIZIKS-UHFFFAOYSA-N methoxide Chemical compound [O-]C NBTOZLQBSIZIKS-UHFFFAOYSA-N 0.000 description 2
BCTONXHZFGFJIT-UHFFFAOYSA-N n-[(2,6-dimethylphenyl)methyl]-1,2-dimethylbenzimidazol-4-amine Chemical compound C1=CC=C2N(C)C(C)=NC2=C1NCC1=C(C)C=CC=C1C BCTONXHZFGFJIT-UHFFFAOYSA-N 0.000 description 2
JDHSOEOZYCQKQU-UHFFFAOYSA-N n-[(4-fluoro-2,6-dimethylphenyl)methyl]-1,2-dimethylbenzimidazol-4-amine Chemical compound C1=CC=C2N(C)C(C)=NC2=C1NCC1=C(C)C=C(F)C=C1C JDHSOEOZYCQKQU-UHFFFAOYSA-N 0.000 description 2
CQQOZDBMROIOHX-UHFFFAOYSA-N n-[(4-fluoro-2,6-dimethylphenyl)methyl]-2-methyl-1h-benzimidazol-4-amine Chemical compound C=12NC(C)=NC2=CC=CC=1NCC1=C(C)C=C(F)C=C1C CQQOZDBMROIOHX-UHFFFAOYSA-N 0.000 description 2
230000007935 neutral effect Effects 0.000 description 2
LSQZJLSUYDQPKJ-UHFFFAOYSA-N p-Hydroxyampicillin Natural products O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)C(N)C1=CC=C(O)C=C1 LSQZJLSUYDQPKJ-UHFFFAOYSA-N 0.000 description 2
239000003208 petroleum Substances 0.000 description 2
229920001223 polyethylene glycol Polymers 0.000 description 2
229910000027 potassium carbonate Inorganic materials 0.000 description 2
239000002244 precipitate Substances 0.000 description 2
230000004044 response Effects 0.000 description 2
230000003248 secreting effect Effects 0.000 description 2
235000009518 sodium iodide Nutrition 0.000 description 2
239000000600 sorbitol Substances 0.000 description 2
235000010356 sorbitol Nutrition 0.000 description 2
239000005720 sucrose Substances 0.000 description 2
230000009885 systemic effect Effects 0.000 description 2
235000019364 tetracycline Nutrition 0.000 description 2
150000003522 tetracyclines Chemical class 0.000 description 2
FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 2
125000005424 tosyloxy group Chemical group S(=O)(=O)(C1=CC=C(C)C=C1)O* 0.000 description 2
235000015112 vegetable and seed oil Nutrition 0.000 description 2
239000008158 vegetable oil Substances 0.000 description 2
239000011592 zinc chloride Substances 0.000 description 2
235000005074 zinc chloride Nutrition 0.000 description 2
RYRXRNFGYVEUFO-UHFFFAOYSA-N 1-(2-chloropropan-2-yl)-4-fluorobenzene Chemical compound CC(C)(Cl)C1=CC=C(F)C=C1 RYRXRNFGYVEUFO-UHFFFAOYSA-N 0.000 description 1
RCWIWNUVHNAUQC-UHFFFAOYSA-N 1-fluoro-3,5-dimethylbenzene Chemical compound CC1=CC(C)=CC(F)=C1 RCWIWNUVHNAUQC-UHFFFAOYSA-N 0.000 description 1
HYFDMAKFLLWGOK-UHFFFAOYSA-N 2-(bromomethyl)-5-fluoro-1,3-dimethylbenzene Chemical compound CC1=CC(F)=CC(C)=C1CBr HYFDMAKFLLWGOK-UHFFFAOYSA-N 0.000 description 1
PHKXHIBYXGTHFI-UHFFFAOYSA-N 2-methyl-4-phenylmethoxy-1h-benzimidazole Chemical compound C=12NC(C)=NC2=CC=CC=1OCC1=CC=CC=C1 PHKXHIBYXGTHFI-UHFFFAOYSA-N 0.000 description 1
BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
208000003200 Adenoma Diseases 0.000 description 1
206010001233 Adenoma benign Diseases 0.000 description 1
WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
241000272470 Circus Species 0.000 description 1
IJSOKZYEOAJVRY-UHFFFAOYSA-N Cl.CC1=C(CNC2=CC=CC=3N=C(NC32)C)C(=CC=C1)C Chemical compound Cl.CC1=C(CNC2=CC=CC=3N=C(NC32)C)C(=CC=C1)C IJSOKZYEOAJVRY-UHFFFAOYSA-N 0.000 description 1
229920002261 Corn starch Chemical class 0.000 description 1
208000035944 Duodenal fistula Diseases 0.000 description 1
206010016717 Fistula Diseases 0.000 description 1
PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
206010065713 Gastric Fistula Diseases 0.000 description 1
208000007882 Gastritis Diseases 0.000 description 1
208000012671 Gastrointestinal haemorrhages Diseases 0.000 description 1
CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
229930182566 Gentamicin Natural products 0.000 description 1
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
229910002651 NO3 Inorganic materials 0.000 description 1
NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
229910019142 PO4 Inorganic materials 0.000 description 1
229930040373 Paraformaldehyde Natural products 0.000 description 1
108010079943 Pentagastrin Proteins 0.000 description 1
235000002595 Solanum tuberosum Nutrition 0.000 description 1
244000061456 Solanum tuberosum Species 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
208000007107 Stomach Ulcer Diseases 0.000 description 1
206010042220 Stress ulcer Diseases 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
201000008629 Zollinger-Ellison syndrome Diseases 0.000 description 1
PCBOWMZAEDDKNH-HOTGVXAUSA-N [4-(trifluoromethoxy)phenyl]methyl (3as,6as)-2-(3-fluoro-4-sulfamoylbenzoyl)-1,3,3a,4,6,6a-hexahydropyrrolo[3,4-c]pyrrole-5-carboxylate Chemical compound C1=C(F)C(S(=O)(=O)N)=CC=C1C(=O)N1C[C@H]2CN(C(=O)OCC=3C=CC(OC(F)(F)F)=CC=3)C[C@@H]2C1 PCBOWMZAEDDKNH-HOTGVXAUSA-N 0.000 description 1
230000001154 acute effect Effects 0.000 description 1
150000001298 alcohols Chemical class 0.000 description 1
125000002723 alicyclic group Chemical group 0.000 description 1
125000001931 aliphatic group Chemical group 0.000 description 1
239000003513 alkali Substances 0.000 description 1
229910000102 alkali metal hydride Inorganic materials 0.000 description 1
150000008046 alkali metal hydrides Chemical class 0.000 description 1
150000008044 alkali metal hydroxides Chemical class 0.000 description 1
125000002947 alkylene group Chemical group 0.000 description 1
229960004821 amikacin Drugs 0.000 description 1
LKCWBDHBTVXHDL-RMDFUYIESA-N amikacin Chemical compound O([C@@H]1[C@@H](N)C[C@H]([C@@H]([C@H]1O)O[C@@H]1[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O1)O)NC(=O)[C@@H](O)CCN)[C@H]1O[C@H](CN)[C@@H](O)[C@H](O)[C@H]1O LKCWBDHBTVXHDL-RMDFUYIESA-N 0.000 description 1
229940126575 aminoglycoside Drugs 0.000 description 1
229960000723 ampicillin Drugs 0.000 description 1
AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
239000003242 anti bacterial agent Substances 0.000 description 1
230000001262 anti-secretory effect Effects 0.000 description 1
239000003699 antiulcer agent Substances 0.000 description 1
125000003118 aryl group Chemical group 0.000 description 1
239000003782 beta lactam antibiotic agent Substances 0.000 description 1
230000003115 biocidal effect Effects 0.000 description 1
230000008827 biological function Effects 0.000 description 1
150000001621 bismuth Chemical class 0.000 description 1
230000037396 body weight Effects 0.000 description 1
239000012267 brine Substances 0.000 description 1
GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
229910052794 bromium Inorganic materials 0.000 description 1
230000003139 buffering effect Effects 0.000 description 1
CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
239000008116 calcium stearate Substances 0.000 description 1
235000013539 calcium stearate Nutrition 0.000 description 1
AIXAANGOTKPUOY-UHFFFAOYSA-N carbachol Chemical compound [Cl-].C[N+](C)(C)CCOC(N)=O AIXAANGOTKPUOY-UHFFFAOYSA-N 0.000 description 1
229960004484 carbachol Drugs 0.000 description 1
229910052799 carbon Inorganic materials 0.000 description 1
239000001768 carboxy methyl cellulose Substances 0.000 description 1
235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
239000008112 carboxymethyl-cellulose Substances 0.000 description 1
239000000969 carrier Substances 0.000 description 1
230000003197 catalytic effect Effects 0.000 description 1
QYIYFLOTGYLRGG-GPCCPHFNSA-N cefaclor Chemical compound C1([C@H](C(=O)N[C@@H]2C(N3C(=C(Cl)CS[C@@H]32)C(O)=O)=O)N)=CC=CC=C1 QYIYFLOTGYLRGG-GPCCPHFNSA-N 0.000 description 1
229960005361 cefaclor Drugs 0.000 description 1
229960000603 cefalotin Drugs 0.000 description 1
OKBVVJOGVLARMR-QSWIMTSFSA-N cefixime Chemical compound S1C(N)=NC(C(=N\OCC(O)=O)\C(=O)N[C@@H]2C(N3C(=C(C=C)CS[C@@H]32)C(O)=O)=O)=C1 OKBVVJOGVLARMR-QSWIMTSFSA-N 0.000 description 1
229960002129 cefixime Drugs 0.000 description 1
VUFGUVLLDPOSBC-XRZFDKQNSA-M cephalothin sodium Chemical compound [Na+].N([C@H]1[C@@H]2N(C1=O)C(=C(CS2)COC(=O)C)C([O-])=O)C(=O)CC1=CC=CS1 VUFGUVLLDPOSBC-XRZFDKQNSA-M 0.000 description 1
239000007795 chemical reaction product Substances 0.000 description 1
229960005091 chloramphenicol Drugs 0.000 description 1
WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 1
239000000460 chlorine Substances 0.000 description 1
229910052801 chlorine Inorganic materials 0.000 description 1
229960003405 ciprofloxacin Drugs 0.000 description 1
229960002626 clarithromycin Drugs 0.000 description 1
AGOYDEPGAOXOCK-KCBOHYOISA-N clarithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@](C)([C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)OC)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 AGOYDEPGAOXOCK-KCBOHYOISA-N 0.000 description 1
238000003776 cleavage reaction Methods 0.000 description 1
239000003086 colorant Substances 0.000 description 1
239000008120 corn starch Chemical class 0.000 description 1
239000003085 diluting agent Substances 0.000 description 1
210000001198 duodenum Anatomy 0.000 description 1
IDYZIJYBMGIQMJ-UHFFFAOYSA-N enoxacin Chemical compound N1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCNCC1 IDYZIJYBMGIQMJ-UHFFFAOYSA-N 0.000 description 1
229960002549 enoxacin Drugs 0.000 description 1
229960003276 erythromycin Drugs 0.000 description 1
MVPICKVDHDWCJQ-UHFFFAOYSA-N ethyl 3-pyrrolidin-1-ylpropanoate Chemical compound CCOC(=O)CCN1CCCC1 MVPICKVDHDWCJQ-UHFFFAOYSA-N 0.000 description 1
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
239000000706 filtrate Substances 0.000 description 1
239000012467 final product Substances 0.000 description 1
230000003890 fistula Effects 0.000 description 1
239000000796 flavoring agent Substances 0.000 description 1
229910052731 fluorine Inorganic materials 0.000 description 1
239000011737 fluorine Substances 0.000 description 1
235000013305 food Nutrition 0.000 description 1
235000013355 food flavoring agent Nutrition 0.000 description 1
239000012458 free base Substances 0.000 description 1
201000005917 gastric ulcer Diseases 0.000 description 1
201000000052 gastrinoma Diseases 0.000 description 1
208000021302 gastroesophageal reflux disease Diseases 0.000 description 1
208000030304 gastrointestinal bleeding Diseases 0.000 description 1
229960002518 gentamicin Drugs 0.000 description 1
239000011521 glass Substances 0.000 description 1
239000008103 glucose Substances 0.000 description 1
235000011187 glycerol Nutrition 0.000 description 1
239000008187 granular material Substances 0.000 description 1
125000005842 heteroatom Chemical group 0.000 description 1
125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
229960001340 histamine Drugs 0.000 description 1
229960004931 histamine dihydrochloride Drugs 0.000 description 1
PPZMYIBUHIPZOS-UHFFFAOYSA-N histamine dihydrochloride Chemical compound Cl.Cl.NCCC1=CN=CN1 PPZMYIBUHIPZOS-UHFFFAOYSA-N 0.000 description 1
150000004678 hydrides Chemical class 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
UWYVPFMHMJIBHE-OWOJBTEDSA-N hydroxymaleic acid group Chemical group O/C(/C(=O)O)=C/C(=O)O UWYVPFMHMJIBHE-OWOJBTEDSA-N 0.000 description 1
239000000543 intermediate Substances 0.000 description 1
PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
239000011630 iodine Substances 0.000 description 1
238000005342 ion exchange Methods 0.000 description 1
125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
210000004731 jugular vein Anatomy 0.000 description 1
229960000318 kanamycin Drugs 0.000 description 1
229930027917 kanamycin Natural products 0.000 description 1
SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 1
229930182823 kanamycin A Natural products 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
239000003120 macrolide antibiotic agent Substances 0.000 description 1
229940041033 macrolides Drugs 0.000 description 1
229910052749 magnesium Inorganic materials 0.000 description 1
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Substances [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
229940098779 methanesulfonic acid Drugs 0.000 description 1
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
229960000282 metronidazole Drugs 0.000 description 1
VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 description 1
150000007522 mineralic acids Chemical class 0.000 description 1
210000004400 mucous membrane Anatomy 0.000 description 1
GRNIQEQKQMSSSZ-UHFFFAOYSA-N n-[(2,6-diethylphenyl)methyl]-2-methyl-1h-benzimidazol-4-amine Chemical compound CCC1=CC=CC(CC)=C1CNC1=CC=CC2=C1NC(C)=N2 GRNIQEQKQMSSSZ-UHFFFAOYSA-N 0.000 description 1
QTGWIBNVFTVALF-UHFFFAOYSA-N n-benzyl-2-methyl-1h-benzimidazol-4-amine Chemical compound C=12NC(C)=NC2=CC=CC=1NCC1=CC=CC=C1 QTGWIBNVFTVALF-UHFFFAOYSA-N 0.000 description 1
125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
229960000564 nitrofurantoin Drugs 0.000 description 1
NXFQHRVNIOXGAQ-YCRREMRBSA-N nitrofurantoin Chemical compound O1C([N+](=O)[O-])=CC=C1\C=N\N1C(=O)NC(=O)C1 NXFQHRVNIOXGAQ-YCRREMRBSA-N 0.000 description 1
OGJPXUAPXNRGGI-UHFFFAOYSA-N norfloxacin Chemical compound C1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCNCC1 OGJPXUAPXNRGGI-UHFFFAOYSA-N 0.000 description 1
229960001180 norfloxacin Drugs 0.000 description 1
150000007524 organic acids Chemical class 0.000 description 1
210000000496 pancreas Anatomy 0.000 description 1
229920002866 paraformaldehyde Polymers 0.000 description 1
ANRIQLNBZQLTFV-DZUOILHNSA-N pentagastrin Chemical compound C([C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1[C]2C=CC=CC2=NC=1)NC(=O)CCNC(=O)OC(C)(C)C)CCSC)C(N)=O)C1=CC=CC=C1 ANRIQLNBZQLTFV-DZUOILHNSA-N 0.000 description 1
229960000444 pentagastrin Drugs 0.000 description 1
125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
235000019271 petrolatum Nutrition 0.000 description 1
239000000825 pharmaceutical preparation Substances 0.000 description 1
239000012071 phase Substances 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
239000010452 phosphate Substances 0.000 description 1
230000036470 plasma concentration Effects 0.000 description 1
229920001592 potato starch Chemical class 0.000 description 1
150000007660 quinolones Chemical class 0.000 description 1
238000011084 recovery Methods 0.000 description 1
238000010992 reflux Methods 0.000 description 1
238000012552 review Methods 0.000 description 1
235000019204 saccharin Nutrition 0.000 description 1
CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
229940081974 saccharin Drugs 0.000 description 1
239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
230000007017 scission Effects 0.000 description 1
238000010898 silica gel chromatography Methods 0.000 description 1
229910000033 sodium borohydride Inorganic materials 0.000 description 1
239000012279 sodium borohydride Substances 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
229940045902 sodium stearyl fumarate Drugs 0.000 description 1
HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
239000007790 solid phase Substances 0.000 description 1
239000003381 stabilizer Substances 0.000 description 1
239000008107 starch Substances 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
238000005728 strengthening Methods 0.000 description 1
150000003460 sulfonic acids Chemical class 0.000 description 1
239000000829 suppository Substances 0.000 description 1
238000001356 surgical procedure Methods 0.000 description 1
235000020357 syrup Nutrition 0.000 description 1
239000006188 syrup Substances 0.000 description 1
239000008399 tap water Substances 0.000 description 1
235000020679 tap water Nutrition 0.000 description 1
125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
229960002180 tetracycline Drugs 0.000 description 1
229930101283 tetracycline Natural products 0.000 description 1
229940040944 tetracyclines Drugs 0.000 description 1
DDFYFBUWEBINLX-UHFFFAOYSA-M tetramethylammonium bromide Chemical compound [Br-].C[N+](C)(C)C DDFYFBUWEBINLX-UHFFFAOYSA-M 0.000 description 1
239000002562 thickening agent Substances 0.000 description 1
238000004448 titration Methods 0.000 description 1
230000001562 ulcerogenic effect Effects 0.000 description 1
235000019871 vegetable fat Nutrition 0.000 description 1
239000001993 wax Substances 0.000 description 1
239000002132 β-lactam antibiotic Substances 0.000 description 1
229940124586 β-lactam antibiotics Drugs 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
- C07D235/08—Radicals containing only hydrogen and carbon atoms

Landscapes

Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Bioinformatics & Cheminformatics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Engineering & Computer Science (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

UA98126867A 1996-06-10 1997-05-06 Dervatives of substituted 2-methyl benzimidazole, a method for preparing thereof, a pharmaceutical composition and a method for treatment of gastrointestinal diseases UA64714C2 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
SE9602286A SE9602286D0 (sv)	1996-06-10	1996-06-10	New compounds
PCT/SE1997/000991 WO1997047603A1 (en)	1996-06-10	1997-06-05	New compounds

Publications (1)

Publication Number	Publication Date
UA64714C2 true UA64714C2 (en)	2004-03-15

Family

ID=20402945

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
UA98126867A UA64714C2 (en)	1996-06-10	1997-05-06	Dervatives of substituted 2-methyl benzimidazole, a method for preparing thereof, a pharmaceutical composition and a method for treatment of gastrointestinal diseases

Country Status (33)

Country	Link
US (1)	US6465505B1 (cs)
EP (1)	EP0906288B1 (cs)
JP (1)	JP2000512291A (cs)
CN (1)	CN1101385C (cs)
AR (1)	AR007352A1 (cs)
AT (1)	ATE227273T1 (cs)
AU (1)	AU712173B2 (cs)
BR (1)	BR9709666A (cs)
CA (1)	CA2256687C (cs)
CZ (1)	CZ291469B6 (cs)
DE (1)	DE69716904T2 (cs)
DK (1)	DK0906288T3 (cs)
EE (1)	EE03682B1 (cs)
ES (1)	ES2184097T3 (cs)
HK (1)	HK1017351A1 (cs)
HU (1)	HUP0002952A3 (cs)
ID (1)	ID18431A (cs)
IL (1)	IL127432A0 (cs)
IS (1)	IS1864B (cs)
MY (1)	MY119012A (cs)
NO (1)	NO311672B1 (cs)
NZ (1)	NZ332965A (cs)
PL (1)	PL330525A1 (cs)
PT (1)	PT906288E (cs)
RU (1)	RU2184113C2 (cs)
SA (1)	SA97180427B1 (cs)
SE (1)	SE9602286D0 (cs)
SK (1)	SK282704B6 (cs)
TR (1)	TR199802554T2 (cs)
TW (1)	TW470742B (cs)
UA (1)	UA64714C2 (cs)
WO (1)	WO1997047603A1 (cs)
ZA (1)	ZA974681B (cs)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
SE9704404D0 (sv)	1997-11-28	1997-11-28	Astra Ab	New compounds
AR043063A1 (es) *	2002-12-13	2005-07-13	Altana Pharma Ag	Bencimidazoles 6-sustituidos y su uso como inhibidores de secreciones gastricas
NZ542177A (en) *	2003-04-04	2009-02-28	Altana Pharma Ag	Cyclic benzimidazoles for use against gastrointestinal disorders
AR046893A1 (es) *	2003-12-16	2005-12-28	Altana Pharma Ag	Bencimidazoles triciclicos
AR048869A1 (es) *	2004-04-26	2006-06-07	Altana Pharma Ag	Bencimidazoles triciclicos
AR049168A1 (es) *	2004-05-18	2006-07-05	Altana Pharma Ag	Derivados de benzimidazol
JP2008501766A (ja) *	2004-06-09	2008-01-24	ニコメッドゲゼルシャフトミットベシュレンクテルハフツング	置換された三環式のベンゾイミダゾール
CA2582256A1 (en) *	2004-10-01	2006-04-13	Altana Pharma Ag	Substituted tricyclic benzimidazoles
AR051041A1 (es) *	2004-10-04	2006-12-13	Altana Pharma Ag	Bencimidazoles triciclicos condensados
JP2008543824A (ja) *	2005-06-14	2008-12-04	ファイザー株式会社	アシッドポンプアンタゴニストとしてのクロマン置換ベンゾイミダゾール誘導体
AU2006283876A1 (en) *	2005-08-22	2007-03-01	Nycomed Gmbh	Isotopically substituted benzimidazole derivatives
ATE471319T1 (de) *	2005-12-19	2010-07-15	Raqualia Pharma Inc	Chromansubstituierte benzimidazole und ihre verwendung als säurepumpenhemmer
WO2007072142A2 (en) *	2005-12-19	2007-06-28	Pfizer Japan Inc.	Benzimidazole-5-carboxamide derivatives
US20080027044A1 (en) *	2006-06-13	2008-01-31	Kim Lewis	Prodrug antibiotic screens
JP2010509445A (ja) *	2006-11-10	2010-03-25	ザリージェンツオブザユニヴァーシティーオブカリフォルニア	大気圧プラズマ誘導グラフト重合
US20110046142A1 (en) *	2007-06-13	2011-02-24	Northeastern University	Antibiotic compounds
WO2008151927A2 (en) *	2007-06-15	2008-12-18	Nycomed Gmbh	6-n-substituted benz imidazole derivatives as acid pump antagonists
US8445076B2 (en) *	2008-06-11	2013-05-21	The Regents Of The University Of California	Fouling and scaling resistant nano-structured reverse osmosis membranes
KR101472686B1 (ko)	2013-07-09	2014-12-16	씨제이헬스케어 주식회사	벤즈이미다졸 유도체의 제조방법

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
SE8604566D0 (sv)	1986-10-27	1986-10-27	Haessle Ab	Novel compunds
ATE63550T1 (de) *	1986-10-29	1991-06-15	Binder Dieter	Neue 1-/ 3-(2-dialkylaminoaethoxy)-2-thienyl/-3phenyl-1-propanone und ihre saeureadditionssalze und verfahren zu deren herstellung und sie enthaltende pharmazeutische zusammensetzungen.
US6083961A (en) *	1994-08-03	2000-07-04	Fujisawa Pharmaceutical Co., Ltd.	Benzimidazole compounds as bradykinin antagonists
SE9700661D0 (sv)	1997-02-25	1997-02-25	Astra Ab	New compounds

1996
- 1996-06-10 SE SE9602286A patent/SE9602286D0/xx unknown
1997
- 1997-05-06 UA UA98126867A patent/UA64714C2/uk unknown
- 1997-05-28 ZA ZA974681A patent/ZA974681B/xx unknown
- 1997-05-29 TW TW086107338A patent/TW470742B/zh active
- 1997-05-30 AR ARP970102342A patent/AR007352A1/es unknown
- 1997-06-05 CN CN97196704A patent/CN1101385C/zh not_active Expired - Fee Related
- 1997-06-05 AT AT97927552T patent/ATE227273T1/de not_active IP Right Cessation
- 1997-06-05 DE DE69716904T patent/DE69716904T2/de not_active Expired - Fee Related
- 1997-06-05 HU HU0002952A patent/HUP0002952A3/hu unknown
- 1997-06-05 JP JP10501511A patent/JP2000512291A/ja not_active Ceased
- 1997-06-05 EP EP97927552A patent/EP0906288B1/en not_active Expired - Lifetime
- 1997-06-05 TR TR1998/02554T patent/TR199802554T2/xx unknown
- 1997-06-05 US US08/875,132 patent/US6465505B1/en not_active Expired - Lifetime
- 1997-06-05 PL PL97330525A patent/PL330525A1/xx unknown
- 1997-06-05 CZ CZ19984039A patent/CZ291469B6/cs not_active IP Right Cessation
- 1997-06-05 WO PCT/SE1997/000991 patent/WO1997047603A1/en active IP Right Grant
- 1997-06-05 RU RU99100397/04A patent/RU2184113C2/ru not_active IP Right Cessation
- 1997-06-05 IL IL12743297A patent/IL127432A0/xx unknown
- 1997-06-05 ES ES97927552T patent/ES2184097T3/es not_active Expired - Lifetime
- 1997-06-05 EE EE9800430A patent/EE03682B1/xx not_active IP Right Cessation
- 1997-06-05 BR BR9709666-0A patent/BR9709666A/pt not_active Application Discontinuation
- 1997-06-05 CA CA002256687A patent/CA2256687C/en not_active Expired - Fee Related
- 1997-06-05 PT PT97927552T patent/PT906288E/pt unknown
- 1997-06-05 ID IDP971913A patent/ID18431A/id unknown
- 1997-06-05 NZ NZ332965A patent/NZ332965A/xx unknown
- 1997-06-05 AU AU31992/97A patent/AU712173B2/en not_active Ceased
- 1997-06-05 DK DK97927552T patent/DK0906288T3/da active
- 1997-06-05 SK SK1654-98A patent/SK282704B6/sk unknown
- 1997-06-09 MY MYPI97002563A patent/MY119012A/en unknown
- 1997-09-24 SA SA97180427A patent/SA97180427B1/ar unknown
1998
- 1998-11-25 IS IS4907A patent/IS1864B/is unknown
- 1998-12-09 NO NO19985764A patent/NO311672B1/no unknown
1999
- 1999-05-31 HK HK99102417A patent/HK1017351A1/xx not_active IP Right Cessation

Also Published As

Publication number	Publication date
EP0906288B1 (en)	2002-11-06
ID18431A (id)	1998-04-09
SA97180427B1 (ar)	2005-10-15
IS4907A (is)	1998-11-25
SE9602286D0 (sv)	1996-06-10
HUP0002952A2 (hu)	2001-05-28
MY119012A (en)	2005-03-31
TW470742B (en)	2002-01-01
NO985764L (no)	1998-12-09
NO311672B1 (no)	2002-01-02
AU3199297A (en)	1998-01-07
BR9709666A (pt)	2000-05-09
RU2184113C2 (ru)	2002-06-27
SK165498A3 (en)	1999-06-11
PL330525A1 (en)	1999-05-24
TR199802554T2 (xx)	1999-03-22
IL127432A0 (en)	1999-10-28
CZ291469B6 (cs)	2003-03-12
ZA974681B (en)	1998-08-25
EP0906288A1 (en)	1999-04-07
DE69716904D1 (de)	2002-12-12
SK282704B6 (sk)	2002-11-06
PT906288E (pt)	2003-02-28
CA2256687C (en)	2005-08-09
HUP0002952A3 (en)	2001-11-28
DE69716904T2 (de)	2003-07-24
JP2000512291A (ja)	2000-09-19
CZ403998A3 (cs)	1999-05-12
HK1017351A1 (en)	1999-11-19
US6465505B1 (en)	2002-10-15
DK0906288T3 (da)	2003-01-06
CN1226236A (zh)	1999-08-18
EE9800430A (et)	1999-06-15
CN1101385C (zh)	2003-02-12
ATE227273T1 (de)	2002-11-15
CA2256687A1 (en)	1997-12-18
EE03682B1 (et)	2002-04-15
AU712173B2 (en)	1999-10-28
IS1864B (is)	2003-04-15
ES2184097T3 (es)	2003-04-01
WO1997047603A1 (en)	1997-12-18
NO985764D0 (no)	1998-12-09
AR007352A1 (es)	1999-10-27
NZ332965A (en)	2000-05-26

Publication	Publication Date	Title
UA64714C2 (en)	2004-03-15	Dervatives of substituted 2-methyl benzimidazole, a method for preparing thereof, a pharmaceutical composition and a method for treatment of gastrointestinal diseases
RU2235725C2 (ru)	2004-09-10	Производные имидазопиридина, способ их получения и промежуточные соединения, фармацевтический препарат на их основе (варианты), способ ингибирования секреции желудочной кислоты и способ лечения состояний, в которые вовлечено инфицирование h.pylori
RU2241000C2 (ru)	2004-11-27	Гетероциклические соединения с замещенной фенильной группировкой, способ их получения (варианты), фармацевтические препараты на их основе и способ ингибирования секреции желудочной кислоты
US4520025A (en)	1985-05-28	Bicyclic nitrogen heterocyclic ethers and thioethers, and their pharmaceutical uses
RU2193036C2 (ru)	2002-11-20	Производные имидазо[1,2-а]пиридина, способы их получения, фармацевтический препарат на их основе, способ ингибирования секреции желудочной кислоты, способ лечения желудочно-кишечных воспалительных заболеваний и способ лечения состояний, в которые вовлечено инфицирование h.pylori
EA005377B1 (ru)	2005-02-24	ТЕТРАГИДРОИМИДАЗО [1,2-h][1,7] НАФТИРИДИНОВЫЕ СОЕДИНЕНИЯ
IE840655L (en)	1984-09-16	1,3-thiazolidine derivatives
BG97438A (bg)	1994-03-24	4-алкилимидазолови съединения
RU2294935C2 (ru)	2007-03-10	Имидазопиридиновые производные для применения в терапии в качестве лекарственного средства, ингибирующего протонный насос, и промежуточные соединения для их получения
US4596806A (en)	1986-06-24	7-piperidino-1,2,3,5-tetrahydroimidazo[2,1-b]-quinazolin-2-one having platelet aggregation inhibitory activity
RU2138501C1 (ru)	1999-09-27	Имидазопиридиназолидиноны, их соли и лекарственное средство
US4599346A (en)	1986-07-08	Propan-2-ol derivatives, a process for their production and medicaments containing these compounds
RU2142454C1 (ru)	1999-12-10	Производные 4-амино-3-ацилхинолина, способ их получения, фармацевтический препарат на их основе, способ получения фармацевтического препарата и промежуточное соединение
KR100487029B1 (ko)	2005-11-25	신규화합물
EA003511B1 (ru)	2003-06-26	Производные пиперазинона и их применение
US4108999A (en)	1978-08-22	Thiazolo[3,4-b]isoquinoline derivatives, pharmaceutical compositions containing them and pharmaceutical methods using them
AU697006C (en)	1999-05-06	Compounds for inhibition of gastric acid secretion
MXPA97004136A (en)	1998-02-01	Compounds for inhibition of gastr acid secretion
CA2205896A1 (en)	1996-06-13	Compounds for inhibition of gastric acid secretion
JPH0525170A (ja)	1993-02-02	ピリドン誘導体、その製造法及びそれを含有する抗潰瘍剤
JPH0613486B2 (ja)	1994-02-23	ピリミドン誘導体及びその医薬的に許容される塩
JPH03148262A (ja)	1991-06-25	イミダゾール誘導体およびその製造法ならびにこれを含有する抗潰瘍剤